• The new facility brings together the Scientific and Healthcare Business Units under one roof and includes a dedicated demo room where customers can experience products firsthand.

• The Mumbai office strengthens Esco's presence in India, a key growth market, and strengthens its ability to support the country's rapidly expanding life sciences, healthcare, and biopharmaceutical sectors.

MUMBAI, INDIA, 30 June 2026 – Esco Lifesciences Group is proud to announce the opening of its new Mumbai office in Powai, marking another important milestone in the company's continued investment in India. The new facility will serve as a shared hub for the Scientific and Healthcare Business Units, fostering greater collaboration while enhancing customer engagement and support capabilities across the region.

The Powai office also features a dedicated demonstration room where customers and partners can experience Esco's workflow solutions firsthand. The space supports product demonstrations, training, and technical discussions to strengthen customer engagement and accelerate the adoption of innovative solutions across life sciences, healthcare, and biopharmaceutical applications.

The office opening was marked with a traditional Puja ceremony attended by employees and CEO Xiangqian (“XQ”) Lin, reflecting Esco's appreciation for local culture and traditions.

"India is a strategically important market for Esco and a key driver of our future growth," said XQ Lin. "The opening of our new Mumbai office reflects our confidence in the tremendous opportunities ahead and our commitment to serving customers with greater responsiveness, technical expertise, and local support.”

The new office complements Esco's existing presence in India, including its Medical Business Unit operations in Kandivali, Mumbai, and expands the company's support for scientific research, clinical applications, and biopharmaceutical development nationwide.

The new Mumbai office further strengthens Esco's commitment to better serve customers across India, supporting the continued growth of the country's life sciences and healthcare sectors.